The October 5, 2026 OPUS-1 topline readout is the single most consequential near-term event in the adult pneumococcal vaccine space — but the announcement itself contains no immunogenicity, safety, or efficacy data, making every verdict here conditional on results not yet public. VAX-31's strategic thesis rests on being the broadest-spectrum pneumococcal conjugate vaccine (PCV) in clinical development at 31 serotypes, extending beyond the two closest mechanistic peers with Phase 3 data: V116/Merck (21-valent, Phase 3 RCT STRIDE-3, confirmed mechanistic and contextual fit — same polysaccharide-protein conjugate mechanism, same adult population, same OPA GMT non-inferiority framework vs. [1] PCV20) and VAX-24/Vaxcyte (24-valent, randomized Phase 1/2, confirmed mechanistic fit). V116's STRIDE-3 is the highest-evidence-tier precedent available: it met non-inferiority vs. PCV20 for all 10 shared serotypes and superiority for 10 of 11 unique serotypes, with serotype 15C failing the superiority criterion — establishing that individual serotype failures within an otherwise successful program do not automatically block approval but do constrain label claims. [2] VAX-31's own Phase 1/2 (randomized, 1,015 participants, adults ≥50 years, vs. PCV20) showed mid- and high-dose meeting non-inferiority for all 20 shared serotypes and all 11 novel serotypes meeting the superiority criterion (lower bound ≥2.0), a cleaner early signal than V116 achieved at equivalent stage — but Phase 1/2 data carry materially lower evidentiary weight than STRIDE-3's Phase 3 RCT. [1] The critical statistical risk is scale: with 31 serotypes each requiring the lower bound of the 95% CI of the OPA GMT ratio to exceed 0.5, the probability of at least one serotype narrowly missing the threshold is higher than for any approved predecessor. [3][4] PCV20's serotype 8 near-miss (lower bound 0.49 vs. >0.50 threshold, approved with supportive analyses) and V116's 15C superiority failure are the operative cautionary precedents, both clearing the mechanistic-fit bar. [5][6] No payer or HTA cost-effectiveness data for VAX-31 are present in the inputs. The sharpest risk: OPUS-1's comparator arm is undisclosed, and if it is PCV20 rather than PCV13, the non-inferiority bar for 20 shared serotypes is set against a conjugate vaccine — a more demanding standard than any predecessor faced at the same valency increment. [2]
All VAX-31 immunogenicity conclusions rest on a randomized Phase 1/2 (1,015 participants); OPUS-1 Phase 3 topline data are pending as of the announcement. [1] Phase 1/2 evidence is two tiers below the pivotal Phase 3 RCT standard established by V116/STRIDE-3.
| Indication | Invasive pneumococcal disease (IPD), pneumococcal pneumonia |
| Drug | VAX-31 |
| Company | Vaxcyte, Inc. |
| Trial Phase | Phase 3 |
| Trial Acronym | OPUS-1 |
| Category | Clinical Trial Event |
| Sub Category | Interim Analysis |
| Therapeutic Area | Infectious Diseases & Vaccines |
| Webcast Date | October 5, 2026 |
| Webcast Time | 8:00 a.m. ET / 5:00 a.m. PT |
| Conference ID | PCVX1005 |
| Vaccine Type | 31-valent pneumococcal conjugate vaccine (PCV) |
| Technology Platform | XpressCF® |
| Licensed From | Sutro Biopharma, Inc. |
| Other Pipeline Candidates | VAX-24, VAX-XL, VAX-A1, VAX-GI |
| Other Indications | Group A Strep, Shigella |
Vaxcyte to Present Topline Phase 3 Data for VAX-31
Vaxcyte, Inc. announced it will host a webcast and conference call on October 5, 2026, to present topline data from its pivotal adult Phase 3 OPUS-1 trial. This trial is evaluating the safety, tolerability, and immunogenicity of VAX-31, the company’s 31-valent pneumococcal conjugate vaccine (PCV) candidate. VAX-31 is designed to prevent invasive pneumococcal disease (IPD) and pneumococcal pneumonia, aiming to be the broadest-spectrum PCV candidate in clinical development. The event will provide insights into the vaccine's potential to improve upon current standard-of-care PCVs.
- Vaxcyte is scheduled to present topline results from its adult Phase 3 OPUS-1 trial for VAX-31 via a webcast and conference call on October 5, 2026, at 8:00 a.m. ET. The trial specifically assesses the safety, tolerability, and immunogenicity of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, in preventing invasive pneumococcal disease and pneumococcal pneumonia. This event marks a significant milestone for the company as it prepares to share key findings from its pivotal study.
- VAX-31 stands out as a 31-valent pneumococcal conjugate vaccine candidate, currently the broadest-spectrum PCV in clinical development. It is engineered to cover a wider range of serotypes responsible for a significant portion of IPD, including those associated with high case-fatality rates, antibiotic resistance, and meningitis, while maintaining coverage of previously circulating strains to improve upon existing PCVs.
- Vaxcyte leverages its XpressCF® cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc., to develop high-fidelity vaccines. Beyond VAX-31, the company's pipeline includes VAX-24 (a 24-valent PCV with positive Phase 2 results), VAX-XL (an earlier-stage PCV candidate), VAX-A1 for Group A Strep, and VAX-GI for Shigella, demonstrating a comprehensive approach to bacterial disease prevention.
Why Broader-Spectrum PCVs are Needed for IPD Prevention
Despite significant progress from pneumococcal conjugate vaccine (PCV) programs, substantial residual disease burden persists across multiple populations, driven by serotype replacement, antibiotic resistance, and gaps in protection for high-risk groups. The following unmet needs and at-risk populations have emerged as priorities in recent literature.
Serotype replacement and non-vaccine serotype emergence: Widespread PCV use has driven a shift in pneumococcal disease toward non-vaccine serotypes across all countries where such data are available. Residual and emerging serotypes vary regionally — serotype 8 predominates in Europe and South Africa, while serotype 4 is prominent in the US and Canada. PCV13 serotype 3, known for its severity, continues to persist despite herd immunity effects from existing vaccines.
Children with chronic medical conditions (CMCs): Pediatric individuals under 19 years with CMCs face substantially elevated IPD risk. Adjusted incidence rate ratios (IRRs) for IPD are 7.2 (95% CI: 6.4 to 8.1) for those with one CMC and 128.1 (95% CI: 114.8 to 143.0) for those with two or more CMCs, compared with individuals without a CMC. Immunocompromised children carry the highest risk, with an IRR of 156.1 (95% CI: 133.4 to 182.7).
Elderly adults and pneumococcal pneumonia burden: Pneumococcal pneumonia remains a high burden in adults over 65, with nearly 1.4 million deaths attributable to it in 2019, 50% of whom were over 70 years old, making it the leading cause of deaths from infectious disease worldwide. Serotypes 3, 19A, and 11A are the most commonly identified in this population.
Socially vulnerable and high-risk adult populations: Among Medicare (≥65 years) and Medicaid (ages 19–64) enrollees, all-cause pneumonia (ACP) incidence reaches 8,052 and 1,819 per 100,000 person-years, respectively. High-risk enrollees — those with immunocompromising or other serious conditions such as cancer — in the most socially vulnerable counties show higher ACP incidence than those in the least vulnerable counties, underscoring the compounding effect of social determinants of health.
Antibiotic resistance as a cross-cutting unmet need: Overall antibiotic resistance rates in S. pneumoniae have increased due to rising antibiotic consumption and serotype distribution changes partly driven by PCV rollout. Multidrug resistance was detected in over 94% of isolates in a 2018–2019 Chinese surveillance study, with high resistance to macrolides, tetracycline, and clindamycin. Isolates from pneumococcal pneumonia show higher resistance rates than those from invasive pneumococcal disease, and penicillin-nonsusceptible S. pneumoniae is designated a WHO priority pathogen.
Individuals with inborn errors of immunity (IEI): Optimal pneumococcal protection requires personalized strategies for high-risk cohorts where vaccine effectiveness can be compromised. PPSV23 serves as a diagnostic tool to evaluate a broad spectrum of IEI, particularly humoral defects, though diagnostic challenges persist due to non-standardized assays and a limited panel of unique serotypes available for testing in the PCV era.
Unpacking the OPUS-1 Phase 3 Design for VAX-31 Immunogenicity
Several pivotal trials have evaluated pneumococcal vaccines across adult and elderly populations, spanning conjugate and polysaccharide formulations against invasive pneumococcal disease and community-acquired pneumonia. The studies below capture key design parameters and immunogenicity endpoints that inform the current evidence base for pneumococcal vaccine development and deployment.
| Trial / Study | Population | Design | Vaccine(s) | Primary Endpoints | Key Immunogenicity Measures |
|---|---|---|---|---|---|
| NCT02260882 (PPSV23 Revaccination, Japan) | Adults ≥70 years; primary group (N=81) and revaccination group (N=161, ≥5 years post first dose) | Matched-cohort; single IM dose; blood samples pre- and 4 weeks post-vaccination; AEs collected for 14 days | PPSV23 (first or second dose) | Immunogenicity and safety of PPSV23 revaccination vs. primary vaccination | Serotype-specific IgG GMCs and OPA GMTs pre- and post-vaccination |
| V114-007 (NCT02573181) | Adults ≥65 years with prior PPV23 (≥1 year before); N=250 (125/arm) | Randomized; single dose; safety follow-up 14 days post-vaccination; immunogenicity at Day 30 | PCV15 (V114) vs. PCV13 | Safety profile comparability; IgG GMCs, OPA GMTs, and GMFRs for 13 shared serotypes; antibody responses for 2 PCV15-unique serotypes (22F, 33F) | IgG GMCs, OPA GMTs, GMFRs, and proportions with ≥4-fold rise from baseline |
| PNEU-AGE (NCT03950622) | Adults ≥50 years; N=1,202 (V114 N=602, PCV13 N=600); stratified by age (50–64, 65–74, ≥75 years) | Phase 3, randomized 1:1; single dose; AEs collected post-vaccination; immunogenicity at Day 30 | V114 (PCV15) vs. PCV13 | Noninferiority of V114 vs. PCV13 for 13 shared serotypes; superiority for 2 unique serotypes (22F, 33F); superiority for shared serotype 3 (secondary) | OPA GMTs (ratio V114/PCV13) at Day 30; proportions with ≥4-fold rise from prevaccination |
| PCV20 + BNT162b2 Coadministration (NCT04887948) | Adults ≥65 years; N=570; randomized 1:1:1 | Phase 3, randomized, double-blind, multicentre; immunogenicity at 1 month post-vaccination | PCV20 + BNT162b2 (booster) vs. PCV20 alone vs. BNT162b2 alone | Local reactions, systemic events, AEs, SAEs; immunogenicity of PCV20 and BNT162b2 alone vs. coadministered | OPA GMFRs (baseline to 1 month) across PCV20 serotypes; GMFRs for full-length S-binding IgG and neutralizing titres against SARS-CoV-2 wild-type |
| PCV20 Lot Consistency (NCT03828617) | Pneumococcal vaccine-naive adults 18–49 years; N=1,710 | Phase 3, randomized, multicenter, double-blind; 2:2:2:1 ratio across 3 PCV20 lots and PCV13; immunogenicity ~1 month post-vaccination; SAEs/NDCMCs at 6 months | PCV20 (3 lots) vs. PCV13 | Equivalence of OPA GMTs across 3 PCV20 lots for all 20 serotypes | OPA GMTs, OPA GMFRs, proportions with ≥4-fold rise, proportions with OPA titers ≥lower limit of quantitation |
| PCV13/PPSV23 VE — Kidney Function (Geisinger Health System) | Adults ≥18 years hospitalized with S. pneumoniae urinary antigen testing; 180 cases, 3,889 controls (mean age 69 years) | Test-negative design; multivariable logistic regression controlling for probability of vaccine receipt | PCV13, PPSV23, combined PCV13+PPSV23 | Adjusted VE against S. pneumoniae hospitalization overall and stratified by eGFR (≥60, 30–59, <30 mL/min/1.73 m²) | Adjusted OR-derived VE: PCV13 VE 39% (95% CI 13%–58%); combination VE 39% (95% CI 12%–58%); PPSV23 VE −3.7% (95% CI −57% to 32%) |
| Goto City CAP Surveillance, Japan (2015–2020) | Adults ≥18 years with radiographically confirmed CAP; N=2,103 enrolled | Prospective, population-based, multicenter active surveillance; S. pneumoniae detected by culture, BinaxNOW, and serotype-specific UAD assays | N/A (observational) | Annual incidence of CAP, S. pneumoniae CAP, PCV13-serotype CAP, and PCV20-serotype CAP per 100,000 population | Annual incidences: CAP 1,280; S. pneumoniae CAP 227; PCV13-serotype CAP 63; PCV20-serotype CAP 110 per 100,000 |
| US Adult CAP UAD2 Analysis (2013–2016) | Adults ≥18 years hospitalized with radiographically confirmed CAP; N=12,055 | Prospective; S. pneumoniae identified by culture, BinaxNOW, UAD1 (PCV13 serotypes), and UAD2 (7 PCV20-unique serotypes and 4 additional serotypes) | N/A (observational) | Proportion of CAP cases attributable to PCV13 and PCV20-unique serotypes | PCV13 serotypes: 37.7% (n=559); PCV20-unique serotypes: 27.0% (n=400) of S. pneumoniae-positive CAP cases |
VAX-31's Potential to Redefine PCV Standard of Care
Published comparative data on pneumococcal therapies center primarily on vaccine strategies rather than investigational small-molecule or biologic treatments. The most clinically relevant head-to-head evidence involves higher-valency pneumococcal conjugate vaccines (PCVs) evaluated against established regimens. In the Phase 3 STRIDE-8 trial (NCT05696080), the 21-valent pneumococcal conjugate vaccine V116 was assessed against the sequential PCV15 + PPSV23 regimen in adults 18–64 years of age with conditions associated with increased risk of pneumococcal disease. V116 elicited opsonophagocytic activity (OPA) geometric mean titers (GMTs) and IgG geometric mean concentrations (GMCs) comparable to PCV15 + PPSV23 for the 13 serotypes common between vaccine groups, while producing higher immune responses for the eight serotypes unique to V116. No vaccine-related serious adverse events or deaths were reported, and V116 was well tolerated relative to the comparator regimen.
On the antibiotic treatment side, a multicenter randomized trial across 27 countries compared intravenous-to-oral linezolid (600 mg twice daily) against a cephalosporin regimen (IV ceftriaxone 1 g twice daily followed by oral cefpodoxime 200 mg twice daily) in patients hospitalized with community-acquired pneumonia, with emphasis on Streptococcus pneumoniae. Among all treated patients (linezolid, n = 381; ceftriaxone/cefpodoxime, n = 366), linezolid achieved a higher clinical cure rate than ceftriaxone/cefpodoxime (83.0% vs. 76.4%; p = 0.040). In the subset with S. pneumoniae bacteremia — a marker of invasive disease — linezolid demonstrated a superior clinical cure rate of 93.1% versus 68.2% (p = 0.021). Logistic regression further identified that linezolid-treated patients with bacteremia, pleural effusion, cardiac comorbidities, diabetes, or abnormal white blood cell counts had significantly better outcomes than those receiving the cephalosporin regimen. Microbiologic eradication rates were similar between arms (88.7% vs. 89.9%; p = 0.830), though drug-related adverse events were more frequent with linezolid (21.3% vs. 11.2%; p = 0.0002).
From a population-level vaccine impact perspective, routine infant immunization with seven-valent pneumococcal conjugate vaccine (PCV7) in the USA was associated with a 39% decline (95% CI: 22–52) in all-cause pneumonia admission rates for children younger than 2 years by end of 2004, representing approximately 41,000 pneumonia admissions prevented that year. Pneumococcal-coded pneumonia admission rates in the same age group declined by 65% (95% CI: 47–77). A retrospective analysis of the Pediatric Health Information System further showed a significant 32% decrease in invasive pneumococcal disease (IPD) among healthy children following PCV13 introduction (p = 0.026), though no significant change was observed in children with chronic conditions (9%; p = 0.24). Collectively, these data underscore that while newer conjugate vaccines and select antibiotic regimens demonstrate measurable advantages over current standards in defined populations, gaps in coverage — particularly among immunocompromised patients and those with chronic conditions — remain a persistent clinical challenge.
A New Era for Adult Pneumococcal Vaccines
The upcoming presentation of topline Phase 3 data for Vaxcyte's VAX-31 marks a critical juncture in the fight against pneumococcal disease. Despite the significant impact of current pneumococcal conjugate vaccines (PCVs), a substantial burden of adult pneumococcal disease persists, driven by the diversity of serotypes and the phenomenon of serotype replacement. VAX-31, a 31-valent PCV, is designed to offer the broadest serotype coverage to date, directly addressing these unmet needs.
This ambitious vaccine candidate leverages Vaxcyte's innovative eCRM carrier protein and site-specific conjugation technology. This platform is engineered to overcome the challenge of carrier suppression, which typically limits the number of serotypes that can be effectively included in a single vaccine. Early clinical data for VAX-31 have been highly encouraging, demonstrating a safety profile similar to PCV20 and, notably, achieving non-inferiority for all shared serotypes and superiority for all 11 serotypes unique to VAX-31.
If these compelling Phase 1/2 results are confirmed in the pivotal Phase 3 OPUS-1 trial, the strategic implications are profound. VAX-31 could emerge as a market leader in adult pneumococcal vaccination, setting a new standard of care and significantly influencing public health policy and immunization guidelines globally. Such an outcome would also provide robust validation for Vaxcyte's proprietary vaccine platform, paving the way for future high-valent vaccine developments.
However, several risks warrant consideration. The primary challenge lies in whether the Phase 3 data will fully replicate the strong immunogenicity and favorable safety profile observed in earlier studies across a larger, more diverse adult population. Furthermore, the competitive landscape for adult PCVs is robust, with established 20-valent options. VAX-31's success will hinge on demonstrating a clear, compelling clinical advantage and effectively navigating market access and adoption hurdles. Should VAX-31 deliver on its promise, it stands to redefine the landscape of adult pneumococcal protection, offering a new level of defense against this pervasive pathogen.
Frequently Asked Questions
References
- [1] Isturiz R, Grant L et al.. Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 Oct 5. 33982098
- [2] Cui C, Timbrook TT et al.. Disease burden and high-risk populations for complications in patients with acute respiratory infections: a scoping review. Frontiers in medicine. 2024. 38818396
- [3] Mrabt F, Guedes S. Systematic review on serotypes distribution of pneumococcal pneumonia in adults and the elderly. BMC public health. 2025 Mar 29. 40158111
- [4] Almirall J, Blanquer J et al.. Community-acquired pneumonia among smokers. Archivos de bronconeumologia. 2014 Jun. 24387877
- [5] Sgrulletti M, Mastrototaro MF et al.. Toward Universal Protection: A Comprehensive Review of Pneumococcal Disease, Emerging Vaccination Challenges and Future Perspectives. Vaccines. 2025 Dec 12. 41441703
- [6] Grijalva CG, Nuorti JP et al.. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet (London, England). 2007 Apr 7. 17416262
- [7] Kawakami K, Kishino H et al.. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses. Vaccine. 2016 Jul 19. 27265450
- [8] Peterson JT, Stacey HL et al.. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Human vaccines & immunotherapeutics. 2019. 30427749
- [9] Le D, Chang A et al.. Pneumococcal vaccination effectiveness (PCV13 and PPSV23) in individuals with and without reduced kidney function: a test-negative design study. Clinical kidney journal. 2024 Jun. 38915439
- [10] Lee MG, Lee SH et al.. Comparative Treatment Failure Rates of Respiratory Fluoroquinolones or β-Lactam + Macrolide Versus β-Lactam Alone in the Treatment for Community-Acquired Pneumonia in Adult Outpatients: An Analysis of a Nationally Representative Claims Database. Medicine. 2015 Sep. 26426664
- [11] Wong A, Kramer SC et al.. Assessing the effect of social contact structure on the impact of pneumococcal conjugate vaccines. Scientific reports. 2025 Oct 7. 41057458
- [12] San Pedro GS, Cammarata SK et al.. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scandinavian journal of infectious diseases. 2002. 12477321
- [13] Ricci Conesa H, Skröder H et al.. Clinical and economic burden of acute otitis media caused by Streptococcus pneumoniae in European children, after widespread use of PCVs-A systematic literature review of published evidence. PloS one. 2024. 38564583
- [14] Nie XM, Li YS et al.. Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2018 Jun. 28970157
- [15] Yano A, Imai K et al.. Risk of developing pneumococcal disease in individuals under 19 years of age with chronic medical conditions: a retrospective cohort study using a Japanese insurance claims database. BMJ open. 2026 Jan 23. 41577349
- [16] Takeda H, Sato C et al.. Changes in the Pneumococcal Vaccine Serotypes in Adult Noninvasive Pneumonia after the Introduction of Pneumococcal Conjugate Vaccination for Children. Journal of global infectious diseases. 2019 Jan-Mar. 30814833
- [17] Kanevsky I, Surendran N et al.. Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age. Vaccine. 2023 Oct 26. 37793976
- [18] Platt HL, Cardona JF et al.. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine. 2022 Jan 3. 34507861
- [19] Senders S, Klein NP et al.. Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States. The Pediatric infectious disease journal. 2021 Oct 1. 34525007
- [20] Maeda H, Morimoto K. Global distribution and characteristics of pneumococcal serotypes in adults. Human vaccines & immunotherapeutics. 2025 Dec. 40015240
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com
